• Protocols

• S1803

  OPEN TO ACCRUAL

  PhIII - Daratumumab/rHuPh20 +/- Lenalidomide as Post-ASCT Maint. for MM w/MRD to Direct Tx Duration
  
  

• UW23031

  OPEN TO ACCRUAL

  COMMANDER Trial (COMbination regimens in MM post AHCT to elimiNate MRD utilizing IbERdomide)